Brivanib治疗肝癌的临床研究进展

祁兴顺; 杨曼; 白苇; 任维榕; 樊代明; 韩国宏

doi:10.3969/j.issn.1001-5256.2014.03.006

Brivanib治疗肝癌的临床研究进展

DOI: 10.3969/j.issn.1001-5256.2014.03.006

第四军医大学西京消化病医院

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3362
- HTML全文浏览量: 14
- PDF下载量: 729
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Brivanib for treatment of hepatocellular carcinoma: an overview of clinical trials

摘要

摘要:
Brivanib可同时抑制成纤维细胞生长因子受体（FGFR）-1、FGFR-2、FGFR-3、血管内皮细胞生长因子受体（VEGFR）-2和VEGFR-3,以达到抑制肿瘤新生血管形成及肿瘤细胞生长的作用。旨在总结Brivanib治疗肝癌的进展,已完成的Ⅰ和Ⅱ期临床试验结果均证实了Brivanib在肝癌治疗中的安全性和有效性。然而,1项已完成的Ⅲ期随机双盲安慰剂对照研究表明,Brivanib作为晚期肝癌二线治疗手段（即Sorafenib治疗失败者）并未显著改善患者的总体生存期。另1项Ⅲ期随机双盲对照试验结果也表明,Brivanib作为晚期肝癌一线治疗手段并未比Sorafenib显著改善患者的总体生存期。这2项临床试验的失败使得其他两项有关Brivanib治疗肝癌的临床试验提前终止。通过分析以上研究认为亚组分析以及事先筛选Brivanib可能获益的肝癌患者（即FGF信号途径激活的肝癌患者）也许对进一步探究Brivanib的在肝癌治疗中的角色是必要的。
- 肝肿瘤 /
- brivanib /
- 临床试验 /
- 综述
Abstract:
As an inhibitor of fibroblast growth factor receptor ( FGFR) - 1, FGFR- 2, FGFR- 3, vascular endothelial growth factor receptor ( VEGFR) - 2, and VEGFR- 3, brivanib can inhibit tumor angiogenesis and growth. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety and efficacy of brivanib in the treatment of hepatocellular carcinoma ( HCC) . However, one phase Ⅲ, randomized, double-blind, placebo- controlled study showed that the overall survival was not significantly improved in patients receiving brivanib as a second-line therapy for advanced HCC, who had failed treatment with sorafenib, than in those receiving placebo. Another phase Ⅲ, randomized, double- blind, controlled study also showed that the overall survival was not significantly improved in patients receiving brivanib as a first-line therapy for HCC than in those receiving sorafenib. Due to the failure of the two phase Ⅲ studies, two other ongoing phase Ⅲ clinical trials had to be discontinued. Subgroup analysis and prior selection of patients with FGF who might benefit from brivanib may be necessary for further investigation of brivanib in the therapy for HCC.
- liver heoplasms /
- brivanib /
- clinical trial /
- review

HTML全文

参考文献(11)

[1]ALLEN E, WALTERS IB, HANAHAN D.Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition[J].Clin Cancer Res, 2011, 17 (16) :5299-5310.

[2]AYERS M, FARGNOLI J, LEWIN A, et al.Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist[J].Cancer Res, 2007, 67 (14) :6899-6906.

[3]JONKER DJ, ROSEN LS, SAWYER MB, et al.A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors[J].Ann Oncol, 2011, 22 (6) :1413-1419.

[4]EL-KHOUEIRY A, LENZ HJ, POSEY J, et al.Effects of hepatic impairment on the pharmacokinetics of brivanib in a phase I, open-label, multidose study in patients with hepatocellular carcinoma and other solid tumors[J].J Hepatol, 2009, 50 (Suppl 1) :288.

[5] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.

[6]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.

[7]PARK JW, FINN RS, KIM JS, et al.Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2011, 17 (7) :1973-1983.

[8]FINN RS, KANG YK, MULCAHY M, et al.Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2012, 18 (7) :2090-2098.

[9]JOHNSON P, QIN S, PARK JW, et al.Brivanib versus sorafenib as first-lin therapy in patients with unresectable, advanced hepatocellular carcinoma:Results from the phase 3 BRISK-FL study[J].Hepatoloy, 2012, 56 (6) :1519a-1520a.

[10]LLOVET JM, DECAENS T, RAOUL JL, et al.Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib:results from the Phase 3BRISK-PS study[J].J Hepatol, 2012, 56 (Suppl) :549.

[11]VILLANUEVA A.Rethinking future development of molecular therapies in hepatocellular carcinoma:A bottom-up approach[J].J Hepatol, 2013, 59 (2) :392-395.

施引文献

资源附件(0)

访问统计